Pharma Journalist -

Eisai Co., Ltd. and Biogen Inc. have announced a key regulatory milestone for their Alzheimer’s disease therapy lecanemab-irmb, marketed in the United States as LEQEMBI®. The U.S. Food…
Read More...

WuXi Biologics and HanchorBio Inc. have announced a strategic collaboration aimed at accelerating the development and manufacturing of multiple next-generation bi- and multi-functional…
Read More...

Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, has announced the successful completion of its Series D1…
Read More...

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on next-generation immunotherapies, has entered into a collaboration and exclusive worldwide license…
Read More...

China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

Insilico Medicine and Hygtia Therapeutics have entered into an exclusive global license and co-development agreement to advance ISM8969, an investigational NLRP3 inhibitor designed for…
Read More...

Wugen has received a major regulatory endorsement from the U.S. Food and Drug Administration, which has granted Breakthrough Therapy Designation to its investigational CAR-T cell…
Read More...

Charles River Laboratories International and Gazi University Faculty of Medicine have entered into a strategic collaboration aimed at advancing gene therapy research for rare genetic…
Read More...

NEOK Bio has taken a key step toward clinical development after the U.S. Food and Drug Administration approved its Investigational New Drug application for NEOK001, clearing the way for…
Read More...

Opna Bio, a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, has received a key regulatory boost for its myelofibrosis program. The U.S. Food and…
Read More...